Immunotherapy with heat shock protein 96 to treat gliomas

Chunzhao Li; Yifei Du; Yang Zhang; Nan Ji

doi:10.1186/s41016-020-00211-3

Immunotherapy with heat shock protein 96 to treat gliomas

Chin Neurosurg J. 2020 Sep 3:6:31. doi: 10.1186/s41016-020-00211-3. eCollection 2020.

Authors

Chunzhao Li^#¹, Yifei Du^#², Yang Zhang^{1

3

4}, Nan Ji^{1

3

4}

Affiliations

¹ Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing, 100070 China.
² Beijing Shijitan Hospital, Capital Medical University, No.10 Yangfangdian Road, Fengtai District, Beijing, 100038 China.
³ China National Clinical Research Center Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing, 100070 China.
⁴ Beijing Key Laboratory of Brian Tumor, Beijing Tiantan Hospital Capital Medical University, No.119 South 4th Ring West Road, Fengtai District, Beijing, 100070 China.

^# Contributed equally.

Abstract

Heat shock protein 96 (gp96) is a highly conserved protein in the endoplasmic reticulum. The functions of gp96 include promoting the oncogenesis and progression of glioma. In addition, tumor-derived gp96 can activate anti-tumor immune. Therefore, this protein was used to generate an anti-tumor vaccine and widely applied to glioma therapy. This review summarizes the mechanisms of gp96 in glioma oncogenesis and clinical trials of the gp96 tumor vaccine in glioma treatment.

Keywords: Glioma; Oncogenesis; Tumor vaccine; gp96.

Publication types

Review